Literature DB >> 21808268

Targeted therapies: Using β-blockers to inhibit breast cancer progression.

Desmond G Powe1, Frank Entschladen.   

Abstract

Three recent population studies have translated laboratory investigations into a clinical setting and concur in presenting evidence that suggest a dramatic new role for β-blockers in reducing metastases, tumor recurrence and specific mortality in breast cancer. Should we be skeptical about these controversial findings?

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21808268     DOI： 10.1038/nrclinonc.2011.123

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  9 in total

1.  Beta blockers and breast cancer mortality: a population- based study.

Authors:  Thomas I Barron; Roisin M Connolly; Linda Sharp; Kathleen Bennett; Kala Visvanathan
Journal:  J Clin Oncol       Date:  2011-05-31       Impact factor: 44.544

2.  Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer.

Authors:  Amal Melhem-Bertrandt; Mariana Chavez-Macgregor; Xiudong Lei; Erika N Brown; Richard T Lee; Funda Meric-Bernstam; Anil K Sood; Suzanne D Conzen; Gabriel N Hortobagyi; Ana-Maria Gonzalez-Angulo
Journal:  J Clin Oncol       Date:  2011-05-31       Impact factor: 44.544

3.  Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials.

Authors:  Sripal Bangalore; Sunil Kumar; Sverre E Kjeldsen; Harikrishna Makani; Ehud Grossman; Jørn Wetterslev; Ajay K Gupta; Peter S Sever; Christian Gluud; Franz H Messerli
Journal:  Lancet Oncol       Date:  2010-11-29       Impact factor: 41.316

4.  Aspirin use, colorectal cancer survival, and loss to follow-up.

Authors:  Anna E Coghill; Polly A Newcomb; John D Potter
Journal:  JAMA       Date:  2009-12-16       Impact factor: 56.272

5.  Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study.

Authors:  D G Powe; M J Voss; H O Habashy; K S Zänker; A R Green; I O Ellis; F Entschladen
Journal:  Breast Cancer Res Treat       Date:  2011-02-06       Impact factor: 4.872

6.  The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers.

Authors:  Daniel Palm; Kerstin Lang; Bernd Niggemann; Theodore L Drell; Kai Masur; Kurt S Zaenker; Frank Entschladen
Journal:  Int J Cancer       Date:  2006-06-01       Impact factor: 7.396

7.  The sympathetic nervous system induces a metastatic switch in primary breast cancer.

Authors:  Erica K Sloan; Saul J Priceman; Benjamin F Cox; Stephanie Yu; Matthew A Pimentel; Veera Tangkanangnukul; Jesusa M G Arevalo; Kouki Morizono; Breanne D W Karanikolas; Lily Wu; Anil K Sood; Steven W Cole
Journal:  Cancer Res       Date:  2010-09-07       Impact factor: 12.701

8.  Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival.

Authors:  Desmond G Powe; Melanie J Voss; Kurt S Zänker; Hany O Habashy; Andrew R Green; Ian O Ellis; Frank Entschladen
Journal:  Oncotarget       Date:  2010-11

9.  Beta-adrenergic signaling, a novel target for cancer therapy?

Authors:  Hildegard M Schuller
Journal:  Oncotarget       Date:  2010-11
  9 in total
  41 in total

1.  Chronic exposure to stress hormones promotes transformation and tumorigenicity of 3T3 mouse fibroblasts.

Authors:  Melanie S Flint; Andrew Baum; Britteny Episcopo; Kelly Z Knickelbein; Angela J Liegey Dougall; William H Chambers; Frank J Jenkins
Journal:  Stress       Date:  2012-05-16       Impact factor: 3.493

Review 2.  Neuroendocrine influences on cancer progression.

Authors:  Guillermo N Armaiz-Pena; Steve W Cole; Susan K Lutgendorf; Anil K Sood
Journal:  Brain Behav Immun       Date:  2012-06-21       Impact factor: 7.217

Review 3.  Sympathetic nervous system regulation of the tumour microenvironment.

Authors:  Steven W Cole; Archana S Nagaraja; Susan K Lutgendorf; Paige A Green; Anil K Sood
Journal:  Nat Rev Cancer       Date:  2015-09       Impact factor: 60.716

4.  Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study.

Authors:  Gitte Vrelits Sørensen; Patricia A Ganz; Steven W Cole; Lars A Pedersen; Henrik Toft Sørensen; Deirdre P Cronin-Fenton; Jens Peter Garne; Peer M Christiansen; Timothy L Lash; Thomas P Ahern
Journal:  J Clin Oncol       Date:  2013-05-06       Impact factor: 44.544

5.  Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy.

Authors:  Mehmet Asim Bilen; Jean-Bernard Durand; Lacey McQuinn; Kenneth R Hess; Siqing Fu; Gerald S Falchook; David S Hong; Jennifer J Wheler; Rabih Said; Michael S Ewer; Razelle Kurzrock; Aung Naing
Journal:  Invest New Drugs       Date:  2014-04-26       Impact factor: 3.850

6.  β-Adrenergic receptors suppress Rap1B prenylation and promote the metastatic phenotype in breast cancer cells.

Authors:  Jessica M Wilson; Ellen Lorimer; Michael D Tyburski; Carol L Williams
Journal:  Cancer Biol Ther       Date:  2015-07-24       Impact factor: 4.742

7.  Pharmacological blockade of a β(2)AR-β-arrestin-1 signaling cascade prevents the accumulation of DNA damage in a behavioral stress model.

Authors:  Makoto R Hara; Benjamin D Sachs; Marc G Caron; Robert J Lefkowitz
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

8.  Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Authors:  Juan Carlos Plana; Maurizio Galderisi; Ana Barac; Michael S Ewer; Bonnie Ky; Marielle Scherrer-Crosbie; Javier Ganame; Igal A Sebag; Deborah A Agler; Luigi P Badano; Jose Banchs; Daniela Cardinale; Joseph Carver; Manuel Cerqueira; Jeanne M DeCara; Thor Edvardsen; Scott D Flamm; Thomas Force; Brian P Griffin; Guy Jerusalem; Jennifer E Liu; Andreia Magalhães; Thomas Marwick; Liza Y Sanchez; Rosa Sicari; Hector R Villarraga; Patrizio Lancellotti
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2014-10       Impact factor: 6.875

Review 9.  Schwann cells: a new player in the tumor microenvironment.

Authors:  Yuri L Bunimovich; Anton A Keskinov; Galina V Shurin; Michael R Shurin
Journal:  Cancer Immunol Immunother       Date:  2016-11-24       Impact factor: 6.968

10.  Individual differences in pre-carcinogen cytokine and corticosterone concentrations and depressive-like behavior predict tumor onset in rats exposed to a carcinogen.

Authors:  Leah M Pyter; Brian J Prendergast
Journal:  Psychoneuroendocrinology       Date:  2012-10-06       Impact factor: 4.905
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.